We also clarify potential mechanisms that operate for both EZH2 monotherapy and combination therapy in TCL, revealing the activation of STAT1 as one of the tumor-suppressive pathways contributing to the anti-tumor effects. The gene discussed is STAT1; the disease is neoplasm.